Promising areas of pharmacotherapy for obesity
The increasing prevalence of obesity, accompanied by an increase in the frequency of metabolic disorders, hypertension, associated conditions and diseases, dictates the need to optimize preventive and therapeutic strategies of the health care system, including pharmacological approaches to correctin...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2021-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4279 |
| _version_ | 1797856686603501568 |
|---|---|
| author | M. A. Druzhilov T. Yu. Kuznetsova G. A. Chumakova |
| author_facet | M. A. Druzhilov T. Yu. Kuznetsova G. A. Chumakova |
| author_sort | M. A. Druzhilov |
| collection | DOAJ |
| description | The increasing prevalence of obesity, accompanied by an increase in the frequency of metabolic disorders, hypertension, associated conditions and diseases, dictates the need to optimize preventive and therapeutic strategies of the health care system, including pharmacological approaches to correcting obesity and the related risk. The evolution of this area led both to the disappearance of drugs that increase the risks of cardiovascular events, cancer, mental disorders or having other pronounced adverse effects, and to the emergence of unique drugs that not only lead to a decrease in body mass index, but also allow multifactorial effect on various components of adiposopathy or visceral obesity, among which glucagon-like peptide-1 receptor agonist liraglutide is currently registered with the indication for obesity. In this regard, the study continues in this regard and other representatives of this class, as well as drugs from sodium-glucose cotransporter-2 inhibitors group. Many other promising pharmacological agents are currently being studied, a review of which is presented in this article. |
| first_indexed | 2024-04-09T20:44:35Z |
| format | Article |
| id | doaj.art-73e37da74af54ee69f5b087182ecf545 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:44:35Z |
| publishDate | 2021-04-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-73e37da74af54ee69f5b087182ecf5452023-03-29T21:23:37Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202021-04-0126310.15829/1560-4071-2021-42793141Promising areas of pharmacotherapy for obesityM. A. Druzhilov0T. Yu. Kuznetsova1G. A. Chumakova2Petrozavodsk State UniversityPetrozavodsk State UniversityAltai State Medical University; Research Institute for Complex Issues of Cardiovascular DiseasesThe increasing prevalence of obesity, accompanied by an increase in the frequency of metabolic disorders, hypertension, associated conditions and diseases, dictates the need to optimize preventive and therapeutic strategies of the health care system, including pharmacological approaches to correcting obesity and the related risk. The evolution of this area led both to the disappearance of drugs that increase the risks of cardiovascular events, cancer, mental disorders or having other pronounced adverse effects, and to the emergence of unique drugs that not only lead to a decrease in body mass index, but also allow multifactorial effect on various components of adiposopathy or visceral obesity, among which glucagon-like peptide-1 receptor agonist liraglutide is currently registered with the indication for obesity. In this regard, the study continues in this regard and other representatives of this class, as well as drugs from sodium-glucose cotransporter-2 inhibitors group. Many other promising pharmacological agents are currently being studied, a review of which is presented in this article.https://russjcardiol.elpub.ru/jour/article/view/4279obesitycardiorenometabolic riskglucagon-like peptide-1 receptor agonistsgliflozins |
| spellingShingle | M. A. Druzhilov T. Yu. Kuznetsova G. A. Chumakova Promising areas of pharmacotherapy for obesity Российский кардиологический журнал obesity cardiorenometabolic risk glucagon-like peptide-1 receptor agonists gliflozins |
| title | Promising areas of pharmacotherapy for obesity |
| title_full | Promising areas of pharmacotherapy for obesity |
| title_fullStr | Promising areas of pharmacotherapy for obesity |
| title_full_unstemmed | Promising areas of pharmacotherapy for obesity |
| title_short | Promising areas of pharmacotherapy for obesity |
| title_sort | promising areas of pharmacotherapy for obesity |
| topic | obesity cardiorenometabolic risk glucagon-like peptide-1 receptor agonists gliflozins |
| url | https://russjcardiol.elpub.ru/jour/article/view/4279 |
| work_keys_str_mv | AT madruzhilov promisingareasofpharmacotherapyforobesity AT tyukuznetsova promisingareasofpharmacotherapyforobesity AT gachumakova promisingareasofpharmacotherapyforobesity |